The Food and Drug Administration on Friday approved two gene therapies to treat sickle cell disease, one of the which is the first CRISPR/Cas9-based treatment to win regulatory approval in the US. The ...

A red quarter of a circle with the words 'The Quarter Mark' beside it. A year-long series looking back on the most significant moments of the past 25 years, how they changed our world, and how they ...

Researchers have been able to manipulate large chunks of genetic code for almost 50 years. But it is only within the past decade that they have been able to do it with exquisite precision – adding, ...

CRISPR Therapeutics recently obtained approval for its gene therapy Casgevy. The therapy could generate close to $4 billion in annual revenue at its peak. A product approval and strong balance sheet ...

CRISPR Therapeutics (NASDAQ: CRSP) has put itself on the map of the healthcare industry as a serious player in gene editing. Now that it has an approved treatment in Casgevy, there's undoubtedly going ...